Fig 2: CD200-C200R affects the paclitaxel sensitivity in mouse xenografts through regulating CTSK. Stably transfected plasmid or CD200 HeLa cells were used to establish xenografts. After injection for 7 days, 3.6 mg/kg MK-0822 (CTSK inhibitor) was orally treated every week, and 5 mg/kg paclitaxel was administrated by tail vein twice a week. (A) Tumor size was measured every week. (B) Images of xenografts and tumor weight. (C) Positive expression of Ki-67 in tumor tissues of each group. Scale = 50 μm. NS: no significance. **P < 0.01.

Fig 3: CD200-CD200R is involved in the response to cisplatin or paclitaxel in cervical cancer. (A) Schematic diagram shows a coculture system of M2 macrophage-like THP-1 cells and cancer cells. Cell viabilities of HeLa (B) and Siha (C) cells were analyzed by CCK-8. Cell invasion of HeLa (D) and Siha (E) cells was analyzed by Transwell assay. The images of Transwell assay are provided in Supplemental Fig. 6. *P < 0.05, **P < 0.01.

Fig 4: CD200-CD200R affects the chemosensitivity of cervical cancer cells through regulating the CTSK-mediated p65 NF-κB pathway. Cancer cells were treated with 0.1 μg/mL rCTSK as a control to compare the effects of C200-CD200R on resistance to cisplatin or paclitaxel. Cell viabilities of HeLa (A) and Siha (B) were analyzed by CCK-8. Expression of p-p65 NF-κB/p65 NF-κB protein in HeLa (C) and Siha (D) was analyzed by Western blotting. The full length of blots was provided in Supplemental materials. **P < 0.01.

Fig 5: CD200 and CTSK expression in cervical cancer tissues. (A) The GEPIA online website was used to analyze CD200 and CTSK expression in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) tissues and normal tissues. (B) The correlation of CD200 and CTSK in the CESC. CD200 (C) and CTSK (D) expression in tumor tissues and para-cancerous tissues was measured using immunohistochemistry. *P < 0.05, **P < 0.01. Representative images of CD200 and CTSK expression in tissues are provided in Supplemental Fig. 1 and Fig. 2.